FibroBiologics (FBLG) Expected to Release Earnings on Thursday

FibroBiologics (NASDAQ:FBLG) is anticipated to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect FibroBiologics to post earnings of ($0.93) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:00 PM ET.

FibroBiologics (NASDAQ:FBLG) last announced its earnings results on Thursday, April 30th. The company reported ($1.33) EPS for the quarter, hitting analysts’ consensus estimates of ($1.33). On average, analysts expect FibroBiologics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

FibroBiologics Stock Performance

Shares of FibroBiologics stock opened at $0.74 on Thursday. The stock has a market cap of $4.50 million, a price-to-earnings ratio of -0.11 and a beta of 1.14. The stock has a 50 day moving average price of $0.92 and a 200-day moving average price of $3.24. FibroBiologics has a one year low of $0.73 and a one year high of $14.40.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wall Street Zen upgraded FibroBiologics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. D. Boral Capital reissued a “hold” rating on shares of FibroBiologics in a research report on Thursday, March 26th. HC Wainwright restated a “buy” rating and set a $8.00 target price (up from $4.00) on shares of FibroBiologics in a research report on Thursday, April 16th. Weiss Ratings downgraded FibroBiologics from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 7th. Finally, Maxim Group downgraded FibroBiologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $74.00.

Hedge Funds Weigh In On FibroBiologics

A number of hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new position in shares of FibroBiologics during the first quarter worth approximately $29,000. XTX Topco Ltd boosted its holdings in shares of FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after purchasing an additional 28,276 shares during the period. Jane Street Group LLC bought a new position in FibroBiologics in the fourth quarter worth approximately $34,000. Marshall Wace LLP bought a new position in FibroBiologics in the second quarter worth approximately $49,000. Finally, Renaissance Technologies LLC increased its holdings in FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock worth $52,000 after purchasing an additional 171,800 shares during the period.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.